Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net income (loss)	$ 112	$ (34)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Amortization of operating lease right-of-use assets	902	803
Depreciation and amortization	319	351
Deferred income taxes (benefit)	125	72
Accretion of financing instruments, amortization of prepaid financing costs and other	12	12
Compensation expense on employee stock options	252	320
Unrealized (gain) loss on investment in iBio Stock	0	(27)
Realized loss on sale of iBio Stock	0	35
Bad debt (charge offs) expense, net	(36)	3
Gain on disposal of fixed assets	1	(1)
Changes in operating assets and liabilities:
Accounts receivable	(120)	374
Inventories	(983)	794
Prepaid expenses and other assets	(12)	34
Operating lease obligations	(902)	(804)
Accounts payable	244	(921)
Accrued expenses and other current liabilities	1,029	221
Net cash provided by operating activities	943	1,232
Cash flows from investing activities:
Purchase of property and equipment	(553)	(116)
Proceeds from sale of iBio Stock	0	4
Proceeds from sale of fixed assets	0	1
Net cash used in investing activities	(553)	(111)
Cash flows from financing activities:
Repayments of advances under revolving credit facility, net	0	(101)
Proceeds from exercises of stock options	13	0
Repayments under financed lease obligations	(42)	(35)
Net cash used in financing activities	(29)	(136)
Net increase in cash	361	985
Cash at beginning of fiscal year	1,316	331
Cash at end of fiscal year	1,677	1,316
Supplemental disclosures of cash flow information:
Interest	42	41
Income taxes	37	0
Supplemental disclosures of non-cash transactions:
Acquisition of right-of-use asset, net and operating lease obligations, net	60	1,560
Trade in value on like-kind exchanges	$ 1	$ 0